23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
05 mars 2024 16h30 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral...
Pharmacogenomics Market is Expected to Reach $5.8 Billion | MarketsandMarkets™
04 mars 2024 07h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, March 04, 2024 (GLOBE NEWSWIRE) -- Pharmacogenomics market in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR...
Berkshire Sterile Manufacturing Announces the Launch of Its Webinar Series, Perfecting Fill Finish
28 févr. 2024 13h00 HE
|
Berkshire Sterile Manufacturing
Lee, MA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish CDMO and subsidiary of Sharp, will launch a webinar series, Perfecting Fill...
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
27 févr. 2024 08h00 HE
|
Healis Therapeutics
CKDB-501A, a novel BoNT/A neuromodulator protein, completed a Phase 3 trial to investigate the efficacy and safety in treating the glabella.
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
23 févr. 2024 13h50 HE
|
Spherix Global Insights
EXTON, PA, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer biosimilar...
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
22 févr. 2024 15h04 HE
|
Spherix Global Insights
EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation...
[Latest] Global Industrial Protective Clothing Market Size/Share Worth USD 20.63 Billion by 2032 at a 5.98% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
20 févr. 2024 15h00 HE
|
Custom Market Insights
Austin, TX, USA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Industrial Protective Clothing Market Size, Trends and Insights By Product (Heat...
[Latest] Global Citrus Oil Market Size/Share Worth USD 16.2 Billion by 2032 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19 févr. 2024 02h30 HE
|
Custom Market Insights
Austin, TX, USA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Citrus Oil Market Size, Trends and Insights By Source (Oranges, Tangerines,...
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
15 févr. 2024 18h35 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of...
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
15 févr. 2024 08h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Numerous reports indicate that the fibromyalgia treatment market is positioned to continue to grow at a...